These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17696564)

  • 1. Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions.
    Wang TY; Rao SV
    Am J Cardiovasc Drugs; 2007; 7(4):225-33. PubMed ID: 17696564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment.
    Rymer JA; Rao SV
    Coron Artery Dis; 2018 Mar; 29(2):161-167. PubMed ID: 29280914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness.
    Hardy JF; Bélisle S; Van der Linden P
    N Engl J Med; 2002 Aug; 347(9):696-7; author reply 696-7. PubMed ID: 12200566
    [No Abstract]   [Full Text] [Related]  

  • 4. Anemia and blood transfusion: prognostic implications in patients undergoing contemporary percutaneous coronary intervention.
    Moscucci M
    Curr Cardiol Rep; 2009 Sep; 11(5):363-8. PubMed ID: 19709496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anemia as an independent predictor of poor long-term outcomes after percutaneous coronary intervention].
    Liu XM; Kang JP; Lü Q; Liu XH; Wu XS; Ma CS
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):114-6. PubMed ID: 18683796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention.
    Voeltz MD; Patel AD; Feit F; Fazel R; Lincoff AM; Manoukian SV
    Am J Cardiol; 2007 Jun; 99(11):1513-7. PubMed ID: 17531572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion associated microchimerism: a heretofore little-recognized complication following transfusion.
    Kunadian V; Zorkun C; Gibson WJ; Nethala N; Harrigan C; Palmer AM; Ogando KJ; Biller LH; Lord EE; Williams SP; Lew ME; Ciaglo LN; Buros JL; Marble SJ; Gibson CM
    J Thromb Thrombolysis; 2009 Jan; 27(1):57-67. PubMed ID: 18766299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness.
    Cothren C; Moore EE; Offner PJ; Haenel JB; Johnson JL
    N Engl J Med; 2002 Apr; 346(14):1097-8. PubMed ID: 11932486
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial oxygen carriers as a possible alternative to red cells in clinical practice.
    Barbosa FT; Jucá MJ; Castro AA; Duarte JL; Barbosa LT
    Sao Paulo Med J; 2009 May; 127(2):97-100. PubMed ID: 19597685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?
    Sergie Z; Mehran R; Stone GW
    Curr Opin Cardiol; 2012 Jul; 27(4):361-7. PubMed ID: 22565142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Oxygen Carriers: Exactly How Close Are We to an Ultimate Product?
    Simoni J
    Artif Organs; 2017 Apr; 41(4):316-318. PubMed ID: 28397406
    [No Abstract]   [Full Text] [Related]  

  • 13. [Autologous blood transfusion with erythropoietin in heart surgery in an anemic patient].
    Watanabe Y; Fuse K; Naruse Y; Kobayashi T; Konishi H; Shibata Y
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Feb; 40(2):282-5. PubMed ID: 1593170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic approach to postoperative anemia].
    Bisbe Vives E; Moltó L
    Rev Esp Anestesiol Reanim; 2015 Jun; 62 Suppl 1():41-4. PubMed ID: 26320343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.
    Nikolsky E; Mehran R; Sadeghi HM; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2009 Jul; 2(7):624-32. PubMed ID: 19628185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia in cancer patients: significance, epidemiology, and current therapy.
    Tchekmedyian NS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of pharmacologic therapies in patient blood management.
    Goodnough LT; Shander A
    Anesth Analg; 2013 Jan; 116(1):15-34. PubMed ID: 23223098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a hemoglobin substitute in the anemic Jehovah's Witness patient.
    Marelli TR
    Crit Care Nurse; 1994 Feb; 14(1):31-8. PubMed ID: 8194324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why we do what we do? Making sense of antithrombotic therapy in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Brener SJ
    JACC Cardiovasc Interv; 2010 Jun; 3(6):678-9. PubMed ID: 20630462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.